NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: IN
Post# of 33
(Total Views: 227)
Posted On: 08/05/2019 3:56:58 PM
NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Reports Positive Preliminary Data from Phase I Clinical Trial of INB03
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported positive preliminary data during a presentation at Cambridge Healthtech Institute’s Seventh Annual Immuno-Oncology Summit in Boston. Per the update, the company’s INB03 is being developed as part of combination immunotherapy to potentially reverse resistance to treatment. In the open-label, dose-escalation Phase I trial, patients with advanced solid tumors received INB03, a novel, second-generation soluble TNF (tumor necrosis factor) inhibitor that works by a dominant-negative technology. Positive preliminary data from the first two cohorts were released today, and the data will be followed by a final report later this year as INmune Bio advances the program into a Phase II study. “The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03,” INmune Bio Chief Executive Officer and Chief Medical Officer RJ Tesi, MD, said in the news release. “All of these goals have been met. Using data from this trial, we have begun planning a Phase II trial using INB03 as part of combination immunotherapy in patients with cancer.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported positive preliminary data during a presentation at Cambridge Healthtech Institute’s Seventh Annual Immuno-Oncology Summit in Boston. Per the update, the company’s INB03 is being developed as part of combination immunotherapy to potentially reverse resistance to treatment. In the open-label, dose-escalation Phase I trial, patients with advanced solid tumors received INB03, a novel, second-generation soluble TNF (tumor necrosis factor) inhibitor that works by a dominant-negative technology. Positive preliminary data from the first two cohorts were released today, and the data will be followed by a final report later this year as INmune Bio advances the program into a Phase II study. “The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03,” INmune Bio Chief Executive Officer and Chief Medical Officer RJ Tesi, MD, said in the news release. “All of these goals have been met. Using data from this trial, we have begun planning a Phase II trial using INB03 as part of combination immunotherapy in patients with cancer.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)INmune Bio Inc. (INMB) Stock Research Links
Scroll down for more posts ▼